To evaluate the therapeutic potential of anti-MSLN Affitins, we designed BiKEs composed of either an Affitin monomer or dimer fused to an anti-CD16 VHH to activate natural killer cells toward hMSLN-expressing cancer cells. This evidence concerns the gene MSLN and cancer.